Medigen Vaccine Financials
| 6547 Stock | TWD 37.75 0.10 0.27% |
Medigen |
Understanding current and past Medigen Vaccine Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Medigen Vaccine's financial statements are interrelated, with each one affecting the others. For example, an increase in Medigen Vaccine's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Medigen Vaccine's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Medigen Vaccine Biologics. Check Medigen Vaccine's Beneish M Score to see the likelihood of Medigen Vaccine's management manipulating its earnings.
Medigen Vaccine Stock Summary
Medigen Vaccine competes with Ruentex Development, Symtek Automation, WiseChip Semiconductor, Novatek Microelectronics, and Leader Electronics. Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp. MEDIGEN VACCINE operates under Biotechnology classification in Taiwan and is traded on Taiwan OTC Exchange.| Instrument | Taiwan Stock View All |
| Exchange | Taiwan OTC Exchange |
| ISIN | TW0006547003 |
| Business Address | No 16, Hu |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.medigenvac.com |
| Phone | 886 2 7745 0830 |
| Currency | TWD - New Taiwan Dollar |
You should never invest in Medigen Vaccine without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Medigen Stock, because this is throwing your money away. Analyzing the key information contained in Medigen Vaccine's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Medigen Vaccine Key Financial Ratios
There are many critical financial ratios that Medigen Vaccine's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Medigen Vaccine Biologics reports annually and quarterly.| Return On Equity | 0.0662 | |||
| Return On Asset | 0.0209 | |||
| Number Of Employees | 16 | |||
| Beta | 0.89 | |||
| Z Score | 48.6 |
Medigen Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Medigen Vaccine's current stock value. Our valuation model uses many indicators to compare Medigen Vaccine value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Medigen Vaccine competition to find correlations between indicators driving Medigen Vaccine's intrinsic value. More Info.Medigen Vaccine Biologics is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.32 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Medigen Vaccine Biologics is roughly 3.17 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Medigen Vaccine's earnings, one of the primary drivers of an investment's value.Medigen Vaccine Biologics Systematic Risk
Medigen Vaccine's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Medigen Vaccine volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Medigen Vaccine Biologics correlated with the market. If Beta is less than 0 Medigen Vaccine generally moves in the opposite direction as compared to the market. If Medigen Vaccine Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Medigen Vaccine Biologics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Medigen Vaccine is generally in the same direction as the market. If Beta > 1 Medigen Vaccine moves generally in the same direction as, but more than the movement of the benchmark.
Medigen Vaccine December 11, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Medigen Vaccine help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Medigen Vaccine Biologics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Medigen Vaccine Biologics based on widely used predictive technical indicators. In general, we focus on analyzing Medigen Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Medigen Vaccine's daily price indicators and compare them against related drivers.
| Information Ratio | (0.32) | |||
| Maximum Drawdown | 7.39 | |||
| Value At Risk | (2.96) | |||
| Potential Upside | 1.91 |
Additional Tools for Medigen Stock Analysis
When running Medigen Vaccine's price analysis, check to measure Medigen Vaccine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medigen Vaccine is operating at the current time. Most of Medigen Vaccine's value examination focuses on studying past and present price action to predict the probability of Medigen Vaccine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medigen Vaccine's price. Additionally, you may evaluate how the addition of Medigen Vaccine to your portfolios can decrease your overall portfolio volatility.